| Company Name | Boehringer Ingelheim Taiwan Limited |
|---|---|
| Protocol Number | 1160.129 |
| Title of Study | GLORIA-AF: Global Registry, on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation. (Phase II/III) |
| Primary Objective | To investigate the patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in non-valvular atrial fibrillation (AF) patients. To collect real world data on important outcome events of antithrombotic treatments for the prevention of stroke. |
| Number of Sites | 10 |
| Period of Study | From：6/14/2013 to：6/14/2020 |
| Number of Patients | 750人 |
| IRB Approval Date | TVGH: 2013/07/30; CHGH: 2013/03/04; CGMH-LK: 2013/07/10; MMH: 2013/06/24; CGH: 2013/07/10; NTUH: 2013/06/21; KMUH: 2013/10/08; NCKUH: 2013/08/30; CHMHKS: 2013/08/20; TCVGH: 2013/09/04 |
| Publication Plan / Date | Unknown |
